"Flutamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Descriptor ID |
D005485
|
| MeSH Number(s) |
D02.065.199.420 D02.092.146.113.420
|
| Concept/Terms |
Eulexin- Eulexin
- Euflex
- Drogenil
- Eulexine
|
Below are MeSH descriptors whose meaning is more general than "Flutamide".
Below are MeSH descriptors whose meaning is more specific than "Flutamide".
This graph shows the total number of publications written about "Flutamide" by people in this website by year, and whether "Flutamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 2 | 4 |
| 1997 | 0 | 3 | 3 |
| 1998 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Flutamide" by people in Profiles.
-
Saha M, Sikder P, Saha A, Shah S, Sultana S, Emran T, Banik A, Islam Z, Islam MS, Sharker SM, Reza HM. QbD Approach towards Robust Design Space for Flutamide/PiperineSelf-Emulsifying Drug Delivery System with Reduced Liver Injury. AAPS PharmSciTech. 2022 Jan 26; 23(1):62.
-
Pike JW, McDowell E, McCahan SM, Johnson KJ. Identification of gene expression changes in postnatal rat foreskin after in utero anti-androgen exposure. Reprod Toxicol. 2014 Aug; 47:42-50.
-
Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer. 2012 Sep 1; 118(17):4139-47.
-
Sheth SU, Palange D, Xu DZ, Wei D, Feketeova E, Lu Q, Reino DC, Qin X, Deitch EA. Testosterone depletion or blockade in male rats protects against trauma hemorrhagic shock-induced distant organ injury by limiting gut injury and subsequent production of biologically active mesenteric lymph. J Trauma. 2011 Dec; 71(6):1652-8.
-
Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol. 2003 Jan; 169(1):245-50.
-
Corn BW, Valicenti RK, Mulholland SG, Hyslop T, Gomella L. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy. Urology. 1998 May; 51(5):782-7.
-
Kelly WK. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol. 1998; 34 Suppl 3:18-23.
-
Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol. 1997 Aug; 15(8):2928-38.
-
Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am. 1997 May; 24(2):421-31.
-
Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU, Cox JD. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst. 1997 Jan 15; 89(2):158-65.